Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993 Jul;61(7):2991-4.
doi: 10.1128/iai.61.7.2991-2994.1993.

Selective inhibition of microbial serine proteases by eNAP-2, an antimicrobial peptide from equine neutrophils

Affiliations

Selective inhibition of microbial serine proteases by eNAP-2, an antimicrobial peptide from equine neutrophils

M A Couto et al. Infect Immun. 1993 Jul.

Abstract

Equine neutrophil antimicrobial peptide 2 (eNAP-2), a recently described antimicrobial peptide isolated from equine neutrophils, was found to selectively inactivate microbial serine proteases (subtilisin A and proteinase K) without inhibiting mammalian serine proteases (human neutrophil elastase, human cathepsin G, and bovine pancreatic trypsin). Although the primary structure of eNAP-2 resembled that of several known antiproteases that belong to the 4-disulfide core peptide family, this pattern of selectivity is unique. eNAP-2 formed a noncovalent complex with native subtilisin A or proteinase K but did not associate with these enzymes if they had been treated with phenylmethylsulfonyl fluoride, a serine protease inhibitor. The eNAP-2-microbial protease complex was disrupted by boiling or by exposure to low pH. We suggest that eNAP-2 exerted selective antiproteinase activity by binding tightly but noncovalently to the active site of subtilisin A or proteinase K. Since microbial exoproteases may act as virulence factors, the combined antimicrobial and antiprotease activities of eNAP-2 could allow it to play an important role in neutrophil-mediated antimicrobial defenses.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Invest. 1985 Oct;76(4):1427-35 - PubMed
    1. Infect Immun. 1984 Jul;45(1):150-4 - PubMed
    1. Biochem Biophys Res Commun. 1988 Aug 15;154(3):1107-13 - PubMed
    1. Crit Rev Biotechnol. 1988;8(2):121-9 - PubMed
    1. Immunol Lett. 1991 Oct;30(2):201-5 - PubMed

Publication types

MeSH terms

LinkOut - more resources